Prevalence of autoimmune and inflammatory diseases and mental health conditions among an alopecia areata cohort from a US administrative claims database
The Journal of Dermatology · 2023-09 · 50 (9) · 1121-1128
DOI: 10.1111/1346-8138.16839 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Dermatology, online erschienen am 08.06.2023. Verfasst von Prethibha George und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pfizer Inc, New York, New York, USA. Hauptthemen laut MEDLINE: Alopecia Areata, Major Depressive Disorder. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Pfizer.
Abstract (Originalsprache)
Alopecia areata (AA) is associated with an increased burden of autoimmune and inflammatory disease and mental health conditions that may have a negative impact on quality of life. However, the exact burden of comorbidities on US patients with AA and the clinical subtypes alopecia totalis (AT) and alopecia universalis (AU) compared with those without AA is not well understood. This retrospective cohort study aimed to assess the incidence rates and prevalence of AA and its clinical subtypes and examine the autoimmune and inflammatory disease and mental health condition diagnosis burden in US patients with AA and a matched cohort without AA. The Optum Clinformatics Data Mart database was used to select patients aged ≥12 years enrolled between October 1, 2016, and September 30, 2020, who had two or more AA diagnosis codes for the AA cohort. Three patients without AA were age‐, sex‐, and race‐matched to each patient with AA. Autoimmune and inflammatory diseases and mental health conditions were evaluated at baseline and up to 2 years after the index date. In total, 8784 patients with AA (599 with AT/AU) and 26 352 matched patients without AA were included. The incidence rate of AA was 17.5 per 100 000 person‐years (PY; AT/AU: 1.1 per 100 000 PY; non‐AT/AU: 16.3 per 100 000 PY), and the prevalence was 54.9 per 100 000 persons (AT/AU: 3.8; non‐AT/AU: 51.2). Patients with AA had a higher prevalence of autoimmune and inflammatory diseases than the matched non‐AA cohort, including allergic rhinitis (24.0% vs 14.5%), asthma (12.8% vs 8.8%), atopic dermatitis (8.3% vs 1.8%), and psoriasis (5.0% vs. 1.6%). The proportions of anxiety (30.7% vs 21.6%) and major depressive disorder (17.5% vs 14.0%) were higher in patients with AA than those without AA. Patients with AT/AU generally had a greater prevalence of autoimmune and inflammatory disease and mental health conditions than patients with non‐AT/AU AA.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Pfizer Inc, New York, New York, USA.
- Mount Sinai Hospital, New York, New York, USA.
- Pfizer Inc, Groton, Connecticut, USA.
Förderung
- Pfizer
Zitieren
APA
George, P., Jagun, O., Liu, Q., Wentworth, C., Napatalung, L., Wolk, R., Anway, S., & Zwillich, S. H. (2023). Prevalence of autoimmune and inflammatory diseases and mental health conditions among an alopecia areata cohort from a US administrative claims database. The Journal of Dermatology, 50(9), 1121-1128. https://doi.org/10.1111/1346-8138.16839
Vancouver
George P, Jagun O, Liu Q, Wentworth C, Napatalung L, Wolk R, et al. Prevalence of autoimmune and inflammatory diseases and mental health conditions among an alopecia areata cohort from a US administrative claims database. The Journal of Dermatology. 2023;50(9):1121-1128. doi:10.1111/1346-8138.16839
BibTeX
@article{George2023,
author = {George, Prethibha and Jagun, Oladayo and Liu, Qing and Wentworth, Charles and Napatalung, Lynne and Wolk, Robert and Anway, Susan and Zwillich, Samuel H},
title = {Prevalence of autoimmune and inflammatory diseases and mental health conditions among an alopecia areata cohort from a US administrative claims database},
journal = {The Journal of Dermatology},
year = {2023},
volume = {50},
number = {9},
pages = {1121--1128},
doi = {10.1111/1346-8138.16839}
}
EUVIMED